Results 111 to 120 of about 75,323 (218)

Individualized T3‐4N+ Rectal Cancer Treatment Strategies: Exploring the Efficacy of Preoperative Synchronized Lateral Lymph Node Simultaneous Integrated Boost Radiation Therapy

Asia-Pacific Journal of Clinical Oncology, Volume 22, Issue 2, Page 215-222, April 2026.
Anatomical Diagram: It shows a cross‐section of the pelvic area highlighting the rectum and lateral lymph nodes, which are the focal points of the treatment strategy discussed in the paper. Flowchart: It outlines the treatment process from preoperative synchronized radiation therapy to the subsequent surgical procedures, illustrating the sequence of ...
Xinjue Shi, Siyao Zhong, Xianbin Zheng, Xianxiu Nan, Xuan Liu, Qiteng Liu, Jing Yuan, Yuyan Gao   +7 more
wiley   +1 more source

Safety and Efficacy Assessment of Trastuzumab Emtansine in Indian Patients With Human Epidermal Growth Factor Receptor 2‐Positive Unresectable Locally Advanced or Metastatic Breast Cancer Previously Treated With Trastuzumab and a Taxane: An Open‐Label, Single‐Arm, Phase IV Study

Asia-Pacific Journal of Clinical Oncology, Volume 22, Issue 2, Page 240-250, April 2026.
A phase IV, single‐arm, open‐label, multicenter study assessing the safety and efficacy of trastuzumab emtansine in Indian patients for the treatment of human epidermal growth factor receptor 2 (HER2)‐positive unresectable locally advanced or metastatic breast cancer who received prior treatment with trastuzumab and a taxane.
Sudeep Gupta, Manish Singhal, Shona Nag, Waseem Abbas, Dinesh Chandra Doval, Hari Goyal, Chirag Shah, Ashish Singh, Radheshyam Naik, Nitesh Rohatgi, Poonam Patil, Shyam Aggarwal, Vinod Raina, Vaibhav Watts   +13 more
wiley   +1 more source

Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial [PDF]

, 2017
Background: Oral capecitabine achieves a superior response rate with an improved safety profile compared with bolus 5-fluorouracil-leucovorin (5-FU/LV) as first-line treatment for patients with metastatic colorectal cancer.
Begbie, S., Borner, M., Burns, W. I., Burris, H. A., Cassidy, J., Garcia-Alfonso, P., Jodrell, D., Koralewski, P., Levine, E. L., Maroun, J., Marschner, N., McKendrick, J., Scheithauer, W., Tujakowski, J., Twelves, C., Van Hazel, G., Wong, A., Zaluski, J.   +17 more
core  

Managing Skin Side Effects Associated With Oncology Treatments: Asian Perspective on Use of Dermocosmetics

Asia-Pacific Journal of Clinical Oncology, Volume 22, Issue 2, Page 186-198, April 2026.
Skin adverse events (AEs) frequently accompany all types of anticancer treatments. This publication discusses how recent international guidance on best‐practices use of dermocosmetics can be adapted to the North Asia region (China, Hong Kong, Japan, Republic of Korea, and Taiwan).
Meng Pan, Jianguo Sun, Makoto Kawashima, You Chan Kim, Mison Chun, Chia‐Yu Chu, Yi‐Hsin Liang, Mee Chang, Delphine Kerob, Brigitte Dreno   +9 more
wiley   +1 more source

Radiological Loco‐Regional Treatments for Cholangiocarcinoma: A Systematic Review of the Literature

Liver International, Volume 46, Issue 4, April 2026.
ABSTRACT Cholangiocarcinoma (CCA) is the second most common primary liver cancer and is being diagnosed with increasing frequency worldwide. We performed a systematic review on radiofrequency (RFA), microwave (MWA), irreversible electroporation (IRE), trans‐arterial chemoembolization (TACE) and selective internal radiation therapy (SIRT) in CCA. Thirty‐
Dimitrios Pallas, Claudia Campani, Olivier Sutter, Pierre Nahon, Nathalie Ganne‐Carrié, Olivier Seror, Jean‐Charles Nault   +6 more
wiley   +1 more source

A pilot study investigating plasma pharmacokinetics and tolerance of oral capecitabine in carcinoma-bearing dogs

BMC Veterinary Research
Background Capecitabine is an oral prodrug of the active metabolite 5-fluorouracil, which has been used effectively in human colorectal, head and neck, and mammary carcinomas.
Sarah Wetzel, Janean Fidel, Dale Whittington, Nicolas F. Villarino   +3 more
doaj   +1 more source

Dermatomyositis as paraneoplastic syndrome of peritoneal and ovarian relapse after long-term complete remission in patient with metastatic bilateral breast cancer [Dermatomiozitis kao paraneoplastički sindrom peritonealnog i ovarijalnog relapsa nakon dugog perioda potpune remisije u bolesnice s metastatskim bilateralnim rakom dojke] [PDF]

, 2012
Dermatomyositis is a rare disease characterised by inflammatory muscle affection and characteristic cutaneous changes. When occuring in a patient with cancer, dermatomyositis may indicate recurrence or progression and poor outcome.
Bolanča, Ante, Camino-Varela, Adriana-Maria, Kirac, Iva, Kusić, Zvonko, Murgić, Jure, Prpić, Marin   +5 more
core  

Use of capecitabine in management of early colon cancer

Cancer Management and Research, 2011
H Hameed, J CassidyBeatson West of Scotland Cancer Centre, Glasgow, Scotland, UKAbstract: Capecitabine (Xeloda®, Roche, Basel, Switzerland) is a pro-drug of 5-fluorouracil (5-FU), and it is converted to 5-FU in the cancer cell by enzymatic ...
Cassidy J, Hameed H
doaj  

[Comment] Total neoadjuvant treatment with short-course radiotherapy followed by sintilimab plus capecitabine-oxaliplatin versus short-course radiotherapy followed by capecitabine-oxaliplatin in patients with locally advanced rectal cancer (SPRING-01): a single-centre, open-label, phase 2, randomised controlled trial

结直肠肛门外科
[Background] Neoadjuvant short-course radiotherapy combined with chemotherapy as total neoadjuvant therapy increases the pathological complete response rate for patients with locally advanced rectal cancer.
Li You
doaj   +1 more source

Efficacy and safety of combining tislelizumab with capecitabine compared to capecitabine alone in the adjuvant treatment of biliary tract cancers: rationale and protocol design for a randomized clinical trial

BMC Cancer
Background Adjuvant therapy with capecitabine is recommended to improve survival for resectable biliary tract cancers (BTC) patients. Considering that the combination of PD-1/PD-L1 inhibitors with chemotherapy has demonstrated a survival benefit over ...
Xubiao Wei, Yabo Jiang, Jinxue Zhou, Hongkun Zhou, Dong Qu, Xiaofei Ye, Yaxin Zheng, Shuqun Cheng   +7 more
doaj   +1 more source